Loading...
XSTO
ENZY
Market cap73mUSD
May 28, Last price  
2.93SEK
1D
-3.30%
1Q
99.32%
Jan 2017
12.32%
IPO
-44.68%
Name

Enzymatica AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
15.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.53%
Rev. gr., 5y
-5.76%
Revenues
46m
-10.47%
0582,000895,00010,489,00019,063,00027,912,00036,482,00059,446,00052,560,00061,306,000111,245,00057,243,00048,948,00050,904,00045,575,000
Net income
-53m
L+6.94%
-190,096-4,987,000-7,568,000-16,208,000-32,393,000-40,830,000-45,006,000-31,445,000-42,579,000-40,979,000-13,221,000-45,393,000-68,657,000-49,728,000-53,179,000
CFO
-61m
L+50.19%
-101,988-4,856,000-7,253,000-18,429,000-40,666,000-37,648,000-38,434,000-22,545,000-28,792,000-37,576,000-10,652,000-35,869,000-64,566,000-40,287,000-60,507,000
Earnings
Jul 16, 2025

Profile

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://www.enzymatica.se/
IPO date
Jun 14, 2011
Employees
21
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
45,575
-10.47%
50,904
4.00%
48,948
-14.49%
Cost of revenue
98,335
102,009
118,491
Unusual Expense (Income)
NOPBT
(52,760)
(51,105)
(69,543)
NOPBT Margin
Operating Taxes
(159)
9
(89)
Tax Rate
NOPAT
(52,601)
(51,114)
(69,454)
Net income
(53,179)
6.94%
(49,728)
-27.57%
(68,657)
51.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
159,262
74,662
BB yield
-46.86%
-10.75%
Debt
Debt current
1,219
1,195
Long-term debt
20,083
22,560
Deferred revenue
Other long-term liabilities
1,022
1
Net debt
(75,212)
12,936
(26,934)
Cash flow
Cash from operating activities
(60,507)
(40,287)
(64,566)
CAPEX
(393)
(730)
(3,717)
Cash from investing activities
(393)
(730)
(3,717)
Cash from financing activities
127,653
(1,388)
87,366
FCF
(69,466)
(42,842)
(75,355)
Balance
Cash
75,212
8,366
50,689
Long term investments
Excess cash
72,933
5,821
48,242
Stockholders' equity
(430,590)
(380,906)
Invested Capital
177,391
525,277
529,514
ROIC
ROCE
EV
Common stock shares outstanding
215,123
177,634
154,302
Price
1.58
-60.00%
3.95
-12.22%
4.50
-48.51%
Market cap
339,895
-51.56%
701,653
1.05%
694,359
-45.84%
EV
264,683
714,589
667,425
EBITDA
(52,760)
(44,597)
(61,766)
EV/EBITDA
Interest
1,906
2,089
997
Interest/NOPBT